Synonyms: Olinvyk® | TRV130 | TRV130A
oliceridine is an approved drug (FDA (2020))
Compound class:
Synthetic organic
Comment: Oliceridine (TRV130) is an opioid compound. It was developed to exhibit biased-signalling (specifically bias towards G protein signalling), with the aim of reducing the adverse effects associated with use of other opioid drugs [1-2].
|
|
References |
1. Chen XT, Pitis P, Liu G, Yuan C, Gotchev D, Cowan CL, Rominger DH, Koblish M, Dewire SM, Crombie AL et al.. (2013)
Structure-activity relationships and discovery of a G protein biased μ opioid receptor ligand, [(3-methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro-[4.5]decan-9-yl]ethyl})amine (TRV130), for the treatment of acute severe pain. J Med Chem, 56 (20): 8019-31. [PMID:24063433] |
2. DeWire SM, Yamashita DS, Rominger DH, Liu G, Cowan CL, Graczyk TM, Chen XT, Pitis PM, Gotchev D, Yuan C et al.. (2013)
A G protein-biased ligand at the μ-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine. J Pharmacol Exp Ther, 344 (3): 708-17. [PMID:23300227] |
3. Soergel DG, Ann Subach R, Sadler B, Connell J, Marion AS, Cowan CL, Violin JD, Lark MW. (2014)
First Clinical Experience With TRV130: Pharmacokinetics and Pharmacodynamics in Healthy Volunteers. J Clin Pharmacol, 54 (3): 351-7. [PMID:24122908] |